Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
Greg.Corboy1 (talk | contribs) |
Greg.Corboy1 (talk | contribs) Tags: Visual edit Mobile edit Mobile web edit |
||
| Line 474: | Line 474: | ||
| | | | ||
|- | |- | ||
| Acute Myeloid Leukemia (AML) with BCR-ABL1||Disease||Kay Weng Choy + Greg | | Acute Myeloid Leukemia (AML) with BCR-ABL1||Disease||Kay Weng Choy + Greg | ||
Corboy (Monash Health) | |||
| | | | ||
| | | | ||
| Line 491: | Line 491: | ||
|Add WHO reference | |Add WHO reference | ||
|- | |- | ||
| Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg | | Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg Corboy (Monash Health) | ||
| | | | ||
| | | | ||
| Line 709: | Line 709: | ||
|Acute Myeloid Leukemia (AML) with Mutated FLT3 | |Acute Myeloid Leukemia (AML) with Mutated FLT3 | ||
|Disease | |Disease | ||
|Kay Weng Choy + Greg | |Kay Weng Choy + Greg Corboy (Monash Health) | ||
| | | | ||
| | | | ||
| Line 1,307: | Line 1,307: | ||
|Greg Corboy (GC) | |Greg Corboy (GC) | ||
| | | | ||
| | |Requested to update 14022022 | ||
|- | |- | ||
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease|| | |T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease|| | ||
| Line 1,395: | Line 1,395: | ||
| ||GC | | ||GC | ||
| | | | ||
| | |Contacted Jan 2022 no reply, followed up with Fabiola Feb 2022 | ||
|- | |- | ||
|Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera | |Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera | ||